ArticleJournal of Cancer2020
Graphene Oxide Nanoparticles Induce Apoptosis in wild-type and CRISPR/Cas9-IGF/IGFBP3 knocked-out Osteosarcoma Cells.
Article in Journal of Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- In vitro bioactivity, cytotoxicity, and gene silencing of graphene oxide as a Bcl-2 siRNA carrier in osteosarcoma cells with in vivo inflammatory response.Scientific reports · 2026Article
- Graphene Oxide (GO) for the Treatment of Bone Cancer: A Systematic Review and Bibliometric Analysis.Nanomaterials (Basel, Switzerland) · 2024Review
- Evaluation of the Antibacterial, Anti-Cervical Cancer Capacity, and Biocompatibility of Different Graphene Oxides.Molecules (Basel, Switzerland) · 2024Article
- Nanomaterials in Targeting Cancer Cells with Nanotherapeutics: Transitioning Towards Responsive Systems.Current pharmaceutical design · 2024Review
- Extracellular vesicles for cancer therapy: potential, progress, and clinical challenges.Frontiers in bioengineering and biotechnology · 2024Review
- Nanosized drug delivery strategies in osteosarcoma chemotherapy.APL bioengineering · 2023Review
- Potential and Progress of 2D Materials in Photomedicine for Cancer Treatment.ACS applied bio materials · 2023Review
- Green synthesis of silver nanoparticles, graphene, and silver-graphene nanocomposite usingIranian journal of basic medical sciences · 2023Article
- Polyhydroxylated Fullerene CJournal of inflammation research · 2023Article
- Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities.Journal of nanobiotechnology · 2022Review
- Nanoparticle Effects on Stress Response Pathways and Nanoparticle-Protein Interactions.International journal of molecular sciences · 2022Review
- Commentary on: SMARCB1 as a novel diagnostic and prognostic biomarker for osteosarcoma.Bioscience reports · 2022Article
- Flake Graphene-Based Nanomaterial Approach for Triggering a Ferroptosis as an Attractive Theranostic Outlook for Tackling Non-Small Lung Cancer: A Mini Review.Materials (Basel, Switzerland) · 2022Review
- Safety assessment of graphene oxide and microcystin-LR complex: a toxicological scenario beyond physical mixture.Particle and fibre toxicology · 2022Article
- Current Progress in Cancer Treatment Using Nanomaterials.Frontiers in oncology · 2022Review
- Cancer-Related Intracellular Signalling Pathways Activated by DOXorubicin/Cyclodextrin-Graphene-Based Nanomaterials.Biomolecules · 2022Article
- Nano-Graphene Oxide-Promoted Epithelial-Mesenchymal Transition of Human Retinal Pigment Epithelial Cells through Regulation of Phospholipase D Signaling.Nanomaterials (Basel, Switzerland) · 2021Article
- Targeting the 'garbage-bin' to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.Bioscience reports · 2021Article
- Bioactive Hydrogels: Design and Characterization of Cellulose-Derived Injectable Composites.Materials (Basel, Switzerland) · 2021Article
- Nanomaterials for cancer therapy: current progress and perspectives.Journal of hematology & oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma affects both adolescents and adults, and some improvement in the survival rate for affected patients has been reached in the last decade. Still, non-specificity and systemic toxicity may limit traditional therapeutic approaches to some extent. The insulin growth factor 1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.